News and Updates

Taking a Stand

At Waxman Strategies, we recognize systemic racism pervades our society. It impacts our personal biases and prejudices. And it impacts our institutions. The answer is not going to come from striving for color blindness, but from embracing and respecting different backgrounds. And we must not lose sight that white privilege exists and has existed since the dawn of our republic.

Building Capacity for Transformative Change in Health Care with Two New Policy Experts

Waxman Strategies is strengthening its firmwide capabilities in political advocacy, regulatory insight, and industry expertise with the appointment of Ruth McDonald and Kahaari Kenyatta to the health policy team.

Remaining Committed

During this historic moment for our country and the planet, we want to mark the moment and update our stakeholders on how we are navigating these uncertain times.

Waxman Strategies Publishes White Paper on Nonprofit Pharmaceutical Companies

Based on the input of experts and nonprofit leaders, our white paper describes challenges in five policy areas and provides a set of policy options for policymakers to consider which could improve the sustainability of the nonprofit model and help to reduce the burden of high prescription drug prices.

Waxman Strategies’ Etelle Higonnet Honored With France’s National Order of Merit

Etelle Higonnet, senior director at Waxman Strategies has been named a Chevalier of France’s Ordre national du Mérite (National Order of Merit) by French President Emmanuel Macron, recognizing her work to protect the environment.

Henry Waxman Applauds Passage of H.R. 3

Today, the House of Representatives passed H.R. 3 – the Elijah E. Cummings Lower Drug Costs Now Act. Chairman Henry Waxman released the following statement in support of the bill’s passage.

Henry Waxman Debunks Pharmaceutical Industry Claims of Innovation Loss, Again

In a blog post for Health Affairs, Chairman Henry Waxman  debunks the age-old industry claim that lower drug costs mean a loss of drug innovation, noting they made the same unsubstantiated claim back in the 1980s during debate on the Hatch-Waxman Act.

Henry Waxman Discusses The Lower Drug Costs Now Act in Health Affairs

In a piece written for Health Affairs this week, our Chairman Henry Waxman discusses the broken pharmaceutical marketplace, how empowering Medicare to negotiate prices with the pharmaceutical industry will make prescription drugs more affordable for everyone, and why we need the Lower Drug Costs Now Act.

Waxman Strategies in Health Affairs

In a piece written for Health Affairs this week, Health Practice Managing Director Kristi Martin joins Jonathan Foley of Westcott Partners and Rob Shriver of IdeaCrew to discuss the Affordable Care Act’s Multi-State Plan Program, lessons learned from its demise and how we can use those lessons to inform discussion on the public option.

Cocktails & Climate Week: Waxman Strategies Goes to NYC

This week, many of us here at Waxman Strategies packed our bags and temporarily relocated to New York City, where we were thrilled to host a reception as an official part of Climate Week NYC. The event, an evening of cocktails, hors d’oeuvres, and conversation, was held at Candle 79, an upscale restaurant with a plant-based menu.